DIAGNOS Provides an Update on Stock Warrants

Diagnos raised $1,287,333 from warrant exercises; large blocks remain outstanding at $0.40.

What the company is saying

Diagnos Inc. reports detailed activity on its stock warrants over the past two months, highlighting both exercises and expiries. The company specifies that 3,218,333 warrants were exercised, generating $1,287,333 in gross proceeds. It lists the exact numbers and amended expiry dates for all expired warrants, demonstrating transparency in capital structure management. Diagnos also discloses the current outstanding warrants—6,715,369, 13,494,459, and 513,248—all exercisable at $0.40 per share, with expiry dates extending as far as June 5, 2027. The announcement is administrative in tone, providing only factual updates without commentary on operational or strategic implications. The company expresses appreciation to shareholders but does not discuss how proceeds will be used or any impact on business operations.

What the data suggests

The data shows Diagnos received $1,287,333 in new capital from the exercise of 3,218,333 warrants in the past two months. Multiple large tranches of warrants expired during the same period, including 8,333,333 and 3,502,931 units, removing potential future dilution from those series. As of October 6, 2026, 20,723,076 warrants remain outstanding, all exercisable at $0.40 per share, with expiry dates ranging from June 5, 2027 onward. The disclosure is precise, listing each warrant batch by issue date, expiry, and amended terms, but does not provide context on the company’s cash position, use of proceeds, or operational performance. The figures confirm a meaningful recent inflow of capital and a significant overhang of warrants that could convert to equity if exercised. There is no evidence in the release of how this capital will affect growth, profitability, or operational milestones.

Analysis

The announcement is strictly factual, providing a detailed administrative update on recent stock warrant exercises, expiries, and the current outstanding warrants. All claims are realised and supported by specific numbers, dates, and terms, with no forward-looking projections or promotional language. There is no discussion of future plans, operational milestones, or financial forecasts, and no attempt to frame the warrant activity as a strategic or value-creating event. The only non-administrative statement is a brief note of gratitude to shareholders, which does not inflate the signal. No large capital outlay or long-term benefit is discussed, and the information is limited to immediate changes in capital structure.

Risk flags

• ●A substantial number of warrants—20,723,076—remain outstanding at $0.40 per share, creating ongoing dilution risk if exercised, which could pressure future share price and affect existing shareholders’ ownership percentages.
• ●The announcement does not disclose how the $1,287,333 in new capital will be allocated or whether it is sufficient to meet near-term operational or strategic needs, leaving uncertainty about the impact on the company’s financial trajectory.
• ●No operational, revenue, or profitability data is provided alongside the capital structure update, making it difficult for investors to assess the company’s underlying business health or the strategic significance of the warrant activity.

Bottom line

Diagnos Inc. has improved its cash position by $1,287,333 through recent warrant exercises, but still faces a large potential dilution from over 20 million outstanding warrants at $0.40 per share. The update is strictly administrative, with no disclosure about how this capital will be used or whether it addresses operational funding needs. Investors are left without insight into the company's financial health, growth plans, or the strategic impact of these transactions. The main takeaway is that while the company has raised new funds, the warrant overhang remains significant and could affect future equity value. Further updates on operational performance or capital allocation would be needed to assess the investment case more fully.

Announcement summary

(OTCQB:DGNOF) Diagnos Inc. announced an update regarding its stock warrants activity over the last two months. During this period, 3,218,333 stock warrants were exercised, generating gross proceeds of $1,287,333. The company also reported the expiry of several batches of stock warrants during the same period. Specifically, 1,414,286 warrants issued on February 27, 2024, originally expiring August 27, 2025, and amended to expire August 5, 2026, have expired. Additionally, 650,000 warrants issued March 22, 2024, originally expiring September 22, 2025, and amended to August 5, 2026, have expired. A further 1,125,000 warrants issued May 9, 2024, originally expiring November 9, 2025, and amended to August 5, 2026, have expired. 3,502,931 warrants issued June 5, 2024, originally expiring December 5, 2025, and amended to August 5, 2026, have expired. 8,333,333 warrants issued September 20, 2024, originally expiring March 20, 2026, and amended to September 5, 2026, have expired. 2,655,691 warrants issued October 25, 2024, originally expiring April 25, 2026, and amended to September 25, 2026, have expired. As of the date of the press release, the company has several outstanding stock warrants. These include 6,715,369 warrants issued February 5, 2025, originally expiring August 5, 2026, and amended to June 5, 2027, which are exercisable at $0.40 per common share. There are also 13,494,459 warrants issued December 5, 2025, originally expiring June 5, 2027, and 513,248 warrants issued December 5, 2025, originally expiring June 5, 2027, both also exercisable at $0.40 per common share. The company expressed gratitude to its shareholders for their ongoing support. All currency figures in the release are stated in Canadian dollars. Diagnos Inc. is dedicated to the early detection of eye-related health issues using Artificial Intelligence techniques. The company’s CARA System is licensed for commercialization in Quebec, Canada, and Saudi Arabia.

Disagree with this article?